Hematology 2021: Myeloma

CME

Key Studies in Multiple Myeloma: Independent Conference Coverage of ASH 2021

Physicians: Maximum of 1.25 AMA PRA Category 1 Credits

Released: May 12, 2022

Expiration: May 11, 2023

Shaji K. Kumar
Shaji K. Kumar, MD
Sagar Lonial
Sagar Lonial, MD, FACP

Activity

Progress
1
Course Completed

References

  1. Voorhees PM, Rodriguez C, Reeves B, et al. Daratumumab plus VRd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN. Blood Adv. 2021;5:1092-1096.
  2. Laubach JP, Kaufman JL, Sborov DW, et al. Daratumumab (dara) plus lenalidomide, bortezomib, and dexamethasone (RVd) in patients (pts) with transplant-eligible newly diagnosed multiple myeloma (NDMM): updated analysis of GRIFFIN after 24 months of maintenance. Program and Abstracts of the 2021 American Society of Hematology Annual Meeting; December 11-14, 2021; Atlanta, Georgia. Abstract 79.
  3. Moreau P, Attal M, Hulin C, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomized, open-label, phase 3 study. Lancet. 2019;394:29-38.
  4. Loiseau HA, Sonneveld P, Moreau P, et al. Daratumumab (dara) with bortezomib, thalidomide, and dexamethasone (VTD) in transplant-eligible patients (pts) with newly diagnosed multiple myeloma (NDMM): analysis of minimal residual disease (MRD) negativity in Cassiopeia part 1 and part 2. Program and Abstracts of the 2021 American Society of Hematology Annual Meeting; December 11-14, 2021; Atlanta, Georgia. Abstract 82.
  5. Goldschmidt H, Mai EK, Nievergall E, et al. Addition of isatuximab to lenalidomide, bortezomib and dexamethasone as induction therapy for newly diagnosed, transplant-eligible multiple myeloma patients: the phase III GMMG-HD7 trial. Program and Abstracts of the 2021 American Society of Hematology Annual Meeting; December 11-14, 2021; Atlanta, Georgia. Abstract 463.
  6. Leypoldt LB, Besemer B, Asemissen AM, et al. Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial. Leukemia. 2022;36:885-888.
  7. Usmani SZ, Alonso AA, Quach H, et al. DREAMM-9: phase I study of belantamab mafodotin plus standard of care in patients with transplant-ineligible newly diagnosed multiple myeloma. Program and Abstracts of the 2021 American Society of Hematology Annual Meeting; December 11-14, 2021; Atlanta, Georgia. Abstract 2738.
  8. Trudel S, McCurdy A, Sutherland HJ, et al. Part 1 results of a dose-finding study of belantamab mafodotin in combination with pomalidomide and dexamethasone for the treatment of relapsed/refractory multiple myeloma (RRMM). Program and Abstracts of the 2021 American Society of Hematology Annual Meeting; December 11-14, 2021; Atlanta, Georgia. Abstract 1653.
  9. Rathi C, Collins J, Struemper H, et al. Population pharmacokinetics of belantamab mafodotin, a BCMA-targeting agent in patients with relapsed/refractory multiple myeloma. CPT: Pharmacometrics Syst Pharmacol. 2021;10:851.
  10. Ferron-Brady G, Rathi C, Collins J, et al. Exposure–response analyses for therapeutic dose selection of belantamab mafodotin in patients with relapsed/refractory multiple myeloma. Clin Pharmaol Ther. 2021;110:1282.
  11. Durie BGM, Hoering A, Sexton R, et al. Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). Blood Cancer J. 2020;10:53.
  12. Terpos E, Gavriatopoulou M, Ntanasis-Stathopoulos I, et al. A phase 1/2, dose and schedule evaluation study to investigate the safety and clinical activity of belantamab mafodotin administered in combination with lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma. Program and Abstracts of the 2021 American Society of Hematology Annual Meeting; December 11-14, 2021; Atlanta, Georgia. Abstract 2736.
  13. Voorhees PM, Kaufman JL, Laubach J, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020;136:936-945.
  14. Gay F, Mina R, Rota-Scalabrini D, et al. Carfilzomib-based induction/consolidation with or without autologous transplant (ASCT) followed by lenalidomide (R) or carfilzomib-lenalidomide (KR) maintenance: efficacy in high-risk patients. Program and Abstracts of the 2021 American Society of Clinical Oncology Annual Meeting; June 4-8, 2021; Chicago, Illinois. Abstract 8002.
  15. Joseph NS, Kaufman JL, Dhodapkar MV, et al. Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma. J Clin Oncol. 2020;38:1928-1937.
  16. Sonneveld P, Broijl A, Gay F, et al. Bortezomib, lenalidomide, and dexamethasone (VRd) ± daratumumab (DARA) in patients (pts) with transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): A multicenter, randomized, phase III study (PERSEUS). Program and Abstracts of the 2019 American Society of Clinical Oncology Annual Meeting; May 31-June 4, 2019. Abstract TPS8055.
  17. Rosiñol L, Oriol A, Rios Tamayo, R, et al. Ixazomib plus lenalidomide/dexamethasone (IRd) versus lenalidomide /dexamethasone (Rd) maintenance after autologous stem cell transplant in patients with newly diagnosed multiple myeloma: results of the Spanish GEM2014MAIN trial. Program and Abstracts of the 2021 American Society of Hematology Annual Meeting; December 11-14, 2021; Atlanta, Georgia. Abstract 466.
  18. Dimopoulos MA, Gay F, Schjesvold F, et al. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomized, placebo-controlled phase 3 trial. Lancet. 2019;393:253-264.
  19. Dimopoulos MA, Spicka I, Quach H, et al. Ixazomib as postinduction maintenance for patients with newly diagnosed multiple myeloma not undergoing autologous stem cell transplantation: the phase III TOURMALINE-MM4 trial. J Clin Oncol. 2020;38:4030-4041.
  20. Kumar SK, Harrison SJ, Cavo M, et al. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomized, double-blind, multicenter, phase 3 trial. Lancet Oncol. 2020;21:1630-1642.
  21. Kumar SK, Harrison SJ, Cavo M, et al. Final overall survival results from BELLINI, a phase 3 study of venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. Program and Abstracts of the 2021 American Society of Hematology Annual Meeting; December 11-14, 2021; Atlanta, Georgia. Abstract 84.
  22. Kumar SK, D’Souza A, Ahah N, et al. A phase 1 first-in-human study of TNB-383B, a BCMA x CD3 bispecific T-cell redirecting antibody, in patients with relapsed/refractory multiple myeloma. Program and Abstracts of the 2021 American Society of Hematology Annual Meeting; December 11-14, 2021; Atlanta, Georgia. Abstract 900.
  23. Kaufman JL, Quach H, Baz R, et al. Safety and preliminary efficacy from the expansion cohort of a phase 1/2 study of venetoclax plus daratumumab and dexamethasone vs daratumumab plus bortezomib and dexamethasone in patients with t(11;14) relapsed/refractory multiple myeloma. Program and Abstracts of the 2021 American Society of Hematology Annual Meeting; December 11-14, 2021; Atlanta, Georgia. Abstract 817.
  24. Lonial S, Popat R, Hulin C, et al. Iberdomide (iber) in combination with dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): results from the dose-expansion phase of the CC-220-MM-001 trial. Program and Abstracts of the 2021 American Society of Hematology Annual Meeting; December 11-14, 2021; Atlanta, Georgia. Abstract 162.
  25. Martin T, Usmani SZ, Berdeja JG, et al. Updated results from CARTITUDE-1: phase 1b/2 study of ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy, in patients with relapsed/refractory multiple myeloma clinically relevant abstract. Program and Abstracts of the 2021 American Society of Hematology Annual Meeting; December 11-14, 2021; Atlanta, Georgia. Abstract 549.
  26. Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021;398.
  27. Anderson LD, Munshi NC, Shah N, et al. Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, in relapsed and refractory multiple myeloma: Updated KarMMa results. ASCO 2021. Abstract 8016.
  28. Mateos MV, Weisel K, De Stefano V, et al. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma. Leukemia. 2022; epub ahead of print.
  29. Stadtmauer EA, Pasquini MC, Blackwell B, et al. Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: results of the BMT CTN 0702 trial. Journal of Clinical Oncology. 2019;37:589.
  30. Palumbo D, Bringhen S, Kumar S, et al. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncology. 2014;15:333.
  31. Hillengrass J, Cohen AD, Delforge M, et al. Updated Results of CARTITUDE-2: ciltacabtagene autoleucel (cilta-cel), a b-cell maturation antigen (BCMA)-directed chimeric antigen receptor t-cell (CAR-t) therapy, in lenalidomide-refractory patients with progressive multiple myeloma (MM) after 1–3 prior lines of therapy. Program and Abstracts of the 2022 TANDEM Transplantation & Cellular Therapy Annual Meeting; April 23-26, 2022. Abstract 73.
  32. Cohen AD, Delforge M, Agha M, et al. Safety and efficacy of Ciltacabtagene Autoleucel (cilta-cel), a chimeric antigen receptor T-cell (CAR-T) therapy directed against b-cell maturation antigen (BCMA) in patients with multiple myeloma (MM) and early relapse after initial therapy: results from CARTITUDE-2. Program and Abstracts of the 2022 TANDEM Transplantation & Cellular Therapy Annual Meeting; April 23-26, 2022. Abstract 61.
  33. Moreau P, Weisel K, Destfano V, et al. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed/refractory multiple myeloma who received ≥3 prior lines of therapy. Program and Abstracts of the 2021 American Society of Hematology Annual Meeting; December 11-14, 2021; Atlanta, Georgia. Abstract 3057.
  34. Zonder JA, Richter J, Bumm N, et al. Early, deep, and durable responses, and low rates of cytokine release syndrome with REGN5458, a BCMA x CD3 bispecific monoclonal antibody, in a phase 1/2 first-in-human study in patients with relapsed/refractory multiple myeloma (RRMM). Program and Abstracts of the 2021 American Society of Hematology Annual Meeting; December 11-14, 2021; Atlanta, Georgia. Abstract 160.
  35. Trudel S, Cohen AD, Krishnan AY, et al. Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed/refractory multiple myeloma (RRMM): updated results from an ongoing phase I study. Program and Abstracts of the 2021 American Society of Hematology Annual Meeting; December 11-14, 2021; Atlanta, Georgia. Abstract 157.
  36. Krishnan AY, Minnema MC, Berdeja, JG, et al. Updated phase 1 results from monumental-1: first-in-human study of talquetamab, a G protein-coupled receptor family C group 5 member D x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma. Program and Abstracts of the 2021 American Society of Hematology Annual Meeting; December 11-14, 2021; Atlanta, Georgia. Abstract 158.
  37. Mouhieddine TH, Van Oekelen OV, Pan, D, et al. Clinical outcomes of relapsed/refractory multiple myeloma patients following treatment with bispecific antibodies (biabs). Program and Abstracts of the 2021 American Society of Hematology Annual Meeting; December 11-14, 2021; Atlanta, Georgia. Abstract 821.
  38. Mailankody S, Diamonte C, Fitzgerald L, et al. Phase I first-in-class trial of MCARH109, a G protein-coupled receptor class C group 5 member D (GPRC5D) targeted CAR T-cell therapy in patients with relapsed or refractory multiple myeloma. Program and Abstracts of the 2021 American Society of Hematology Annual Meeting; December 11-14, 2021; Atlanta, Georgia. Abstract 827.